TW201612314A - Uses of ligustilide for enhancing the efficacy of stem cells on treating autoimmune diseases, cardiovascular diseases, and/or hematological diseases - Google Patents
Uses of ligustilide for enhancing the efficacy of stem cells on treating autoimmune diseases, cardiovascular diseases, and/or hematological diseasesInfo
- Publication number
- TW201612314A TW201612314A TW104119530A TW104119530A TW201612314A TW 201612314 A TW201612314 A TW 201612314A TW 104119530 A TW104119530 A TW 104119530A TW 104119530 A TW104119530 A TW 104119530A TW 201612314 A TW201612314 A TW 201612314A
- Authority
- TW
- Taiwan
- Prior art keywords
- diseases
- stem cells
- ligustilide
- treating autoimmune
- efficacy
- Prior art date
Links
Abstract
A use of ligustilide is provided, including the use of ligustilide to enhance the therapeutic effect of stem cells on treating autoimmune diseases, cardiovascular diseases, and/or hematological diseases, as well as the use of a combination of ligustilide and ligustilide-treated stem cells on the aforementioned stem cell therapy. With the treatment of ligustilide, stem cells can provide an enhanced therapeutic effect. Such treatment especially can increase the expression of differentiation-promoting genes in stem cells, increase the expression of homing-promoting genes in stem cells, and/or decrease the expression of inflammatory genes in stem cells.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW104119530A TWI625392B (en) | 2014-09-17 | 2014-09-17 | Uses of ligustilide for enhancing the efficacy of stem cells on treating autoimmune diseases, cardiovascular diseases, and/or hematological diseases |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW104119530A TWI625392B (en) | 2014-09-17 | 2014-09-17 | Uses of ligustilide for enhancing the efficacy of stem cells on treating autoimmune diseases, cardiovascular diseases, and/or hematological diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
TW201612314A true TW201612314A (en) | 2016-04-01 |
TWI625392B TWI625392B (en) | 2018-06-01 |
Family
ID=56360767
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW104119530A TWI625392B (en) | 2014-09-17 | 2014-09-17 | Uses of ligustilide for enhancing the efficacy of stem cells on treating autoimmune diseases, cardiovascular diseases, and/or hematological diseases |
Country Status (1)
Country | Link |
---|---|
TW (1) | TWI625392B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI781322B (en) * | 2019-05-27 | 2022-10-21 | 台灣粒線體應用技術股份有限公司 | A culture composition and an use for improving the function of mitochondria thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102397272B (en) * | 2010-09-17 | 2013-08-14 | 石药集团恩必普药业有限公司 | Application of butylphthalide and derivatives thereof in preparation of medicines for preventing and treating ALS |
TWI487521B (en) * | 2013-03-12 | 2015-06-11 | Hawking Biolog Technology Co Ltd | Use of phthalide |
-
2014
- 2014-09-17 TW TW104119530A patent/TWI625392B/en active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI781322B (en) * | 2019-05-27 | 2022-10-21 | 台灣粒線體應用技術股份有限公司 | A culture composition and an use for improving the function of mitochondria thereof |
Also Published As
Publication number | Publication date |
---|---|
TWI625392B (en) | 2018-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201790737A1 (en) | COMBINED THERAPY | |
PH12016500841A1 (en) | Combinations of checkpoint inhibitors and therapeutics to treat cancer | |
MY186702A (en) | Compositions and methods of use for treating metabolic disorders | |
CA160630S (en) | Body groomer | |
MX2015007751A (en) | Anti-gdf15 antibodies. | |
MX2017011834A (en) | Peptidomimetic macrocycles and uses thereof. | |
CL2015002807A1 (en) | Combination therapy | |
PE20150223A1 (en) | ANTIBODIES ENHANCED ANTIBODIES AGAINST GROWTH AND DIFFERENTIATION FACTOR-8 AND THE USES OF THEM | |
IN2015DN00895A (en) | ||
MX2017003797A (en) | Peptidomimetic macrocycles and uses thereof. | |
NZ602798A (en) | Treatment of sarcoidosis using placental stem cells | |
MX2015012922A (en) | Cancer treatment using antibodies that bing cell surface grp78. | |
MY185016A (en) | Progenitor cells of mesodermal lineage | |
MY181994A (en) | Immuno-modulatory progenitor (imp) cell | |
TW201611843A (en) | Methods of treatment with arginine deiminase | |
MA40620A (en) | VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION | |
WO2014210037A3 (en) | A composition of mesenchymal stem cells | |
MX2015014344A (en) | Cancer therapy. | |
SG10201804034QA (en) | Methods for treating hypotension | |
TR201902517T4 (en) | Treatment of conditions associated with increased eotaxin with 25-hydroxyvitamin D3. | |
MX2020002852A (en) | Improved treatment of atopic dermatitis with tradipitant. | |
MX2018000052A (en) | Compositions and methods for combination therapy with dengue virus and dendritic cells. | |
MX2020009966A (en) | Dosage forms and therapeutic uses l-4-chlorokynurenine. | |
TW201612313A (en) | Uses of ligustilide | |
MX2023007706A (en) | Nanoparticles for use as a therapeutic vaccine. |